Omega Therapeutics OMNICOM Bond
| OMGA Stock | USD 0.86 0.07 8.86% |
Omega Therapeutics holds a debt-to-equity ratio of 0.148. At present, Omega Therapeutics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Net Debt is expected to grow to about 63 M, whereas Short and Long Term Debt is forecasted to decline to about 3.8 M. With a high degree of financial leverage come high-interest payments, which usually reduce Omega Therapeutics' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Omega Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Omega Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Omega Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Omega Therapeutics' stakeholders.
For most companies, including Omega Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Omega Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Omega Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 3.7701 | Book Value 1.052 | Operating Margin (7.77) | Return On Assets (0.25) | Return On Equity (1.29) |
Omega |
Given the importance of Omega Therapeutics' capital structure, the first step in the capital decision process is for the management of Omega Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Omega Therapeutics to issue bonds at a reasonable cost.
| Popular Name | Omega Therapeutics OMNICOM GROUP INC |
| Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
| Equity ISIN Code | US68217N1054 |
| Bond Issue ISIN Code | US68217FAA03 |
| S&P Rating | Others |
| Maturity Date | Others |
| Issuance Date | Others |
| Coupon | 3.6 % |
Omega Therapeutics Outstanding Bond Obligations
| Boeing Co 2196 | US097023DG73 | Details | |
| HSBC Holdings PLC | US404280DR76 | Details | |
| ON SEMICONDUCTOR P | US682189AQ81 | Details | |
| MGM Resorts International | US552953CD18 | Details | |
| OMNICOM GROUP INC | US68217FAA03 | Details | |
| AerCap Global Aviation | US00773HAA59 | Details |
Understaning Omega Therapeutics Use of Financial Leverage
Omega Therapeutics' financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Omega Therapeutics' total debt position, including all outstanding debt obligations, and compares it with Omega Therapeutics' equity. Financial leverage can amplify the potential profits to Omega Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Omega Therapeutics is unable to cover its debt costs.
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 128.4 M | 134.8 M | |
| Net Debt | 60 M | 63 M | |
| Long Term Debt | 14.9 M | 15.8 M | |
| Short and Long Term Debt | 4 M | 3.8 M | |
| Short Term Debt | 26.6 M | 27.9 M | |
| Long Term Debt Total | 14.9 M | 14.6 M | |
| Net Debt To EBITDA | (0.64) | (0.61) | |
| Debt To Equity | 0.52 | 0.55 | |
| Interest Debt Per Share | 0.56 | 0.31 | |
| Debt To Assets | 0.15 | 0.14 | |
| Long Term Debt To Capitalization | 0.20 | 0.21 | |
| Total Debt To Capitalization | 0.34 | 0.36 | |
| Debt Equity Ratio | 0.52 | 0.55 | |
| Debt Ratio | 0.15 | 0.14 | |
| Cash Flow To Debt Ratio | (3.03) | (3.18) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Omega Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Omega Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Omega Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Omega Therapeutics Stock:Check out the analysis of Omega Therapeutics Fundamentals Over Time. For information on how to trade Omega Stock refer to our How to Trade Omega Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.32) | Revenue Per Share 0.114 | Quarterly Revenue Growth 1.812 | Return On Assets (0.25) | Return On Equity (1.29) |
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Omega Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.